Scinderin基因沉默对人胃癌细胞SGC-7901增殖、转移的影响

Scinderin是一种依赖Ca2＋的肌动蛋白丝（F-actin）切割蛋白,在细胞分泌过程中发挥着重要作用。目前,针对scinderin在人类疾病尤其是肿瘤中的生物学功能研究报道的并不多。该实验通过构建scinderin—shRNA慢病毒载体并感染人胃癌细胞株SGC-7901,于荧光显微镜下观测感染效率,利用RT-qPCR和Western blot实验证实scinderin的沉默效果。运用实时细胞分析4K（RTCA）检测细胞的增殖能力,流式细胞术检测细胞周期变化,Transwell小室检测细胞的迁移能力。结果显示,将构建好的病毒载体成功转入了胃癌细胞SGC-7901。感染scinderin—shRNA病毒载体后,scinderin的mRNA和蛋白质表达水平均受到不同程度的抑制（P〈0．01）,细胞的增殖和迁移能力均显著降低（P〈0．05）,细胞周期阻滞在G2／M期。该研究表明,胃癌细胞SGC-7901中scinderin低表达能有效抑制细胞的增殖和转移能力,这也为scinderin在胃癌演化过程中的机制研究奠定了实验基础。     

单克隆抗体MGd1 对胃癌SGC-7901 细胞增殖和凋亡的影响

目的:研究不同浓度的MGd1对体外培养胃癌细胞SGC-7901增殖及凋亡的影响。方法:采用MTT法测定不同浓度MGd1对SGC-7901生长抑制作用;流式细胞术(FCM)进行细胞凋亡分析。激光共聚焦显微镜观察MGd1抗原(MGd1-Ag)的亚细胞定位。结果:MTT结果显示不同浓度的MGd1均对SGC-7901细胞产生明显的抑制效应(P=0.02);流式细胞术分析发现MGd1可诱导SGC-7901发生凋亡并呈浓度和时间依赖性(P<0.01);共聚焦显微镜结果显示MGd1-Ag主要定位于细胞膜上。结论:以上结果证实胃癌特异性单抗MGd1可抑制SGC-7901的增殖并促进凋亡发生。它可能通过与细胞膜上抗原特异性结合,影响下游信号传导,从而发挥抑制效应。     

长非编码RNA HOTAIR调控胃癌细胞SGC-7901来源肿瘤干细胞样细胞

肿瘤干细胞样细胞具有自我更新、无限增殖和多向分化能力,且受到长非编码RNA（long non-coding RNAs, lncRNAs）的调控。长非编码RNA HOTAIR在人胃癌细胞中表达升高,且具有调控功能。但目前对其在胃癌干细胞样细胞中的功能尚无研究。本研究的目的是探讨胃癌肿瘤干细胞中HOTAIR对肿瘤恶性行为的调控作用。本研究采用无血清培养基在补充细胞因子条件下培养SGC-7901细胞,获得悬浮生长的肿瘤干细胞样细胞微球,检测微球细胞的表面特征因子CD44、CD24及HOTAIR的表达量变化;并通过CCK-8、流式细胞分析及ELISA等技术探讨了HOTAIR对肿瘤干细胞样细胞功能调控作用。结果表明,无血清培养基中获得的肿瘤干细胞样细胞具有自我更新能力,其可连续传代细胞微球的比率为4.75%±0.76%;RT-qPCR检测显示,相对于SGC-7901细胞,肿瘤干细胞样细胞中的HOTAIR表达量明显升高;通过慢病毒干扰技术发现,HOTAIR干扰抑制了HLA-G蛋白分泌、促进肿瘤干细胞样细胞的细胞周期推进、细胞增殖和自我更新能力维持。本研究提示,胃癌细胞系SGC-7901中的肿瘤干细胞样细胞中HOTAIR表达量升高,并可能通过促进肿瘤干细胞样细胞干性调控肿瘤恶性行为。     

探讨As2O3诱导人胃癌SGC-7901细胞凋亡过程中AKT相关 抗凋亡通路表达情况

目的:探讨三氧化二砷诱导胃癌细胞凋亡过程中,对AKT相关抗凋亡通路表达的影响。方法:分别用不同浓度(0μmol/L、7.5μmol/L、10μmol/L、12.5μmol/L和15μmol/L)三氧化二砷(As_2O_3)溶液处理胃癌细胞48 h,倒置显微镜观察细胞凋亡情况,并用Western blot方法检测p70S6kα、p-p70S6kα、p70S6kβ(S6蛋白激酶β,Ribosomal Protein S6 Kinaseβ)、p-p70S6kβ、rpS6、p-rpS6、p-BAD、BAD、p-GSK3β、GSK3β及NF-κB2等蛋白的表达情况与As_2O_3作用浓度之间的关系。结果:随As_2O_3作用细胞的浓度增大,p70S6kα、p-p70S6kα、p70s6kβ、p-p70S6kβ、p-BAD、p-GSK3β、NF-κB2蛋白的表达减少,rpS6、p-rpS6、GSK3β蛋白表达增多,各组间数据经统计学分析,P值均0.05,具有统计学意义。BAD蛋白的表达无明显改变,P0.05。结论:As_2O_3诱导人胃癌SGC-7901细胞凋亡机制中包括AKT相关的多个抗凋亡途径的激活,AKT在其中发挥重要作用。     

单克隆抗体MGd1对胃癌SGC-7901细胞增殖和凋亡的影响

目的：研究不同浓度的MGd1对体外培养胃癌细胞SGC-7901增殖及凋亡的影响。方法：采用MTT法测定不同浓度MGd1对SGC-7901生长抑制作用;流式细胞术（FCM）进行细胞凋亡分析。激光共聚焦显微镜观察MGd1抗原（MGd1-Ag）的亚细胞定位。结果：MTT结果显示不同浓度的MGd1均对SGC-7901细胞产生明显的抑制效应（P=0.02）;流式细胞术分析发现MGd1可诱导SGC-7901发生凋亡并呈浓度和时间依赖性（P〈0.01）;共聚焦显微镜结果显示MGd1-Ag主要定位于细胞膜上。结论：以上结果证实胃癌特异性单抗MGd1可抑制SGC-7901的增殖并促进凋亡发生。它可能通过与细胞膜上抗原特异性结合,影响下游信号传导,从而发挥抑制效应。     

SIRT3 Enhances Glycolysis and Proliferation in SIRT3-Expressing Gastric Cancer Cells

SIRT3 is a key NAD⁺-dependent protein deacetylase in the mitochondria of mammalian cells, functioning to prevent cell aging and transformation via regulation of mitochondrial metabolic homeostasis. However, SIRT3 is also found to express in some human tumors; its role in these SIRT3-expressing tumor cells needs to be elucidated. This study demonstrated that the expression of SIRT3 was elevated in a group of gastric cancer cells compared to normal gastric epithelial cells. Although SIRT3 expression levels were increased in the gastric tumor tissues compared to the adjacent non-tumor tissues, SIRT3 positive cancer cells were more frequently detected in the intestinal type gastric cancers than the diffuse type gastric cancers, indicating that SIRT3 is linked with subtypes of gastric cancer. Overexpression of SIRT3 promoted cell proliferation and enhanced ATP generation, glucose uptake, glycogen formation, MnSOD activity and lactate production, which were inhibited by SIRT3 knockdown, indicating that SIRT3 plays a role in reprogramming the bioenergetics in gastric tumor cells. Further analysis revealed that SIRT3 interacted with and deacetylated the lactate dehydrogenase A (LDHA), a key protein in regulating anaerobic glycolysis, enhancing LDHA activity. In consistence, a cluster of glycolysis-associated genes was upregulated in the SIRT3-overexpressing gastric tumor cells. Thus, in addition to the well-documented SIRT3-mediated mitochondrial homeostasis in normal cells, SIRT3 may enhance glycolysis and cell proliferation in SIRT3-expressing cancer cells.     

MicroRNA-149 Inhibits Proliferation and Cell Cycle Progression through the Targeting of ZBTB2 in Human Gastric Cancer

An increasing body of evidence indicates that miR-149 can both suppress and promote tumor growth depending on the tumor type. However, the role of miR-149 in the progression of gastric cancer (GC) remains unknown. Here we report that miR-149 is a tumor suppressor in human gastric cancer. miR-149 expression is decreased in GC cell lines and clinical specimens in comparison to normal gastric epithelial cell and tissues, respectively. The expression levels of miR-149 also correlate with the differentiation degree of GC cells and tissues. Moreover, ectopic expression of miR-149 in gastric cancer cells inhibits proliferation and cell cycle progression by down-regulating ZBTB2, a potent repressor of the ARF-HDM2-p53-p21 pathway, with a potential binding site for miR-149 in its mRNA''s 3′UTR. It is also found that ZBTB2 expression increases in GC cells and tissues compared to normal gastric epithelial cell and tissues, respectively. Silencing of ZBTB2 leads to suppression of cell growth and cell cycle arrest in G0/G1 phase, indicating that ZBTB2 may act as an oncogene in GC. Furthermore, transfection of miR-149 mimics into gastric cancer cells induces down-regulation of ZBTB2 and HDM2, and up-regulation of ARF, p53, and p21 compared to the controls. In summary, our data suggest that miR-149 functions as a tumor suppressor in human gastric cancer by, at least partially through, targeting ZBTB2.     

姜半夏乙醇提取物对人胃癌SGC7901细胞增殖和凋亡的影响

目的：观察姜半夏乙醇提取物对人胃癌SGC7901细胞增殖和凋亡的影响。方法：不同浓度姜半夏乙醇提取物（终浓度为1mg／ml,0．5mg／ml,0．25mg／ml,0．125mg／ml）处理SGC7901细胞后,倒置相差显微镜下观察细胞的形态学变化;通过甲基噻唑基四唑法检测细胞增殖状况、描绘生长曲线,使用紫外分光光度法观察药物干预后细胞ATP酶活力;AnnexinV．异硫氰酸荧光素（fluorescein isothiocyanate,FITC）／碘化丙啶（propidium iodide,PI）双标记法流式细胞术检测姜半夏乙醇提取物对SGC7901细胞诱导凋亡的情况。结果：不同浓度姜半夏乙醇提取物均能不同程度地抑制人胃癌SGC7901细胞的增殖;在姜半夏乙醇提取物诱导细胞后细胞发生了边缘毛刺、体积缩小等形态学变化,同时可见细胞折光度和贴壁能力下降;Annexin V-F／TC／PI双标记法检测显示姜半夏乙醇提取物可诱导细胞发生凋亡;细胞总ATP酶活力在药物干预72小时后出现明显下降;并且随着药物浓度增加细胞凋亡率、细胞形态异常改变以及ATP酶活力抑制作用均呈上升趋势。结论：姜半夏乙醇提取物可抑制人胃癌SGC7901细胞的增殖,促进其凋亡,抑制细胞ATP酶活力。     

姜半夏乙醇提取物对人胃癌SGC7901 细胞增殖和凋亡的影响

目的:观察姜半夏乙醇提取物对人胃癌SGC7901细胞增殖和凋亡的影响。方法:不同浓度姜半夏乙醇提取物(终浓度为1mg/ml,0.5mg/ml,0.25mg/ml,0.125mg/ml)处理SGC7901细胞后,倒置相差显微镜下观察细胞的形态学变化;通过甲基噻唑基四唑法检测细胞增殖状况、描绘生长曲线,使用紫外分光光度法观察药物干预后细胞ATP酶活力;AnnexinV-异硫氰酸荧光素(fluorescein isothiocyanate,FITC)/碘化丙啶(propidium iodide,PI)双标记法流式细胞术检测姜半夏乙醇提取物对SGC7901细胞诱导凋亡的情况。结果:不同浓度姜半夏乙醇提取物均能不同程度地抑制人胃癌SGC7901细胞的增殖;在姜半夏乙醇提取物诱导细胞后细胞发生了边缘毛刺、体积缩小等形态学变化,同时可见细胞折光度和贴壁能力下降;AnnexinV-FITC/PI双标记法检测显示姜半夏乙醇提取物可诱导细胞发生凋亡;细胞总ATP酶活力在药物干预72小时后出现明显下降;并且随着药物浓度增加细胞凋亡率、细胞形态异常改变以及ATP酶活力抑制作用均呈上升趋势。结论:姜半夏乙醇提取物可抑制人胃癌SGC7901细胞的增殖,促进其凋亡,抑制细胞ATP酶活力。     

c-FLIP在DATS诱导入胃癌SGC-7901细胞凋亡中的作用

目的:探讨二烯丙基三硫(diallyl trisulfide,DATS)诱导入胃癌SGC-7901细胞凋亡及凋亡过程中c-FLIP的变化及意义.方法:采用MTr,westem-blot和细胞免疫组化分别检测DATS对SGC-7901细胞的增殖抑制率及c-FLIP的表达情况.光学显微镜现察凋亡形态,流式细胞术检测凋亡率.结果:MTT结果显示,不同浓度DATS(6,8,10,12,14,16mg.L~(-1)DATS处理SGC-7901细胞24,48小时后,生长抑制率分别为20.4%-79%和36%-90%,DATS抑制作用随浓度及时间逐渐增强(P<0.05).细胞免疫组化和western-blot显示:9.5mg..L~(-1)DATS处理SGC-7901细胞24,48小时后,与对照组相比,c-FLIP的表达下调(P<0.05).光学显微镜:通过9.5mg..L~(-1)DATS作用后24,48小时后,胃癌细胞出现了凋亡形态学改变.流式细胞术检测:经过9.5mg..L~(-1)DATS处理SGC-7901细胞24,48小时后,细胞凋亡率逐渐升高.结论:DATS促进SGC-7901细胞凋亡的机制可能与抑制c-FLIP蛋白的表达有关.     

c—FLIP在DATS诱导人胃癌SGC-7901细胞凋亡中的作用

目的：探讨二烯丙基三硫（diallyl trisulfide,DATS）诱导人胃癌SGC-7901细胞凋亡及凋亡过程中c-FLIP的变化及意义。方法采用MTT、western-blot和细胞免疫组化分别检测DATS对SGC-7901细胞的增殖抑制率及c-FLIP的表达情况。光学显微镜观察凋亡形态,流式细胞术检测凋亡率。结果：MTT结果显示,不同浓度DATS（6、8、10、12、14、16mg.L^-1）DATS处理SGC-7901细胞24、48小时后,生长抑制率分别为20.4%--79%和36%--90%,DATS抑制作用随浓度及时间逐渐增强（P〈0.05）。细胞免疫组化和western-blot显示：9.5mg..L^-1DATS处理SGC-7901细胞24、48小时后,与对照组相比,c-FLIP的表达下调（P〈0.05）。光学显微镜：通过9.5mg..L^-1DATS作用后24、48小时后,胃癌细胞出现了凋亡形态学改变。流式细胞术检测：经过9.5mg..L^-1DATS处理SGC-7901细胞24、48小时后,细胞凋亡率逐渐升高。结论：DATS促进SGC-7901细胞凋亡的机制可能与抑制c-FLIP蛋白的表达有关。     

Mycophenolic Acid Inhibits Migration and Invasion of Gastric Cancer Cells via Multiple Molecular Pathways

Mycophenolic acid (MPA) is the metabolized product and active element of mycophenolate mofetil (MMF) that has been widely used for the prevention of acute graft rejection. MPA potently inhibits inosine monophosphate dehydrogenase (IMPDH) that is up-regulated in many tumors and MPA is known to inhibit cancer cell proliferation as well as fibroblast and endothelial cell migration. In this study, we demonstrated for the first time MPA’s antimigratory and anti-invasion abilities of MPA-sensitive AGS (gastric cancer) cells. Genome-wide expression analyses using Illumina whole genome microarrays identified 50 genes with ≥2 fold changes and 15 genes with > 4 fold alterations and multiple molecular pathways implicated in cell migration. Real-time RT-PCR analyses of selected genes also confirmed the expression differences. Furthermore, targeted proteomic analyses identified several proteins altered by MPA treatment. Our results indicate that MPA modulates gastric cancer cell migration through down-regulation of a large number of genes (PRKCA, DOCK1, INF2, HSPA5, LRP8 and PDGFRA) and proteins (PRKCA, AKT, SRC, CD147 and MMP1) with promigratory functions as well as up-regulation of a number of genes with antimigratory functions (ATF3, SMAD3, CITED2 and CEAMCAM1). However, a few genes that may promote migration (CYR61 and NOS3) were up-regulated. Therefore, MPA’s overall antimigratory role on cancer cells reflects a balance between promigratory and antimigratory signals influenced by MPA treatment.     

Carnosine Inhibits Growth of Cells Isolated from Human Glioblastoma Multiforme

The present study evaluates the effect of the naturally occurring dipeptide carnosine on primary cell cultures established from patients with glioblastoma multiforme. Surgically removed tumors were used to establish primary cell cultures that were incubated for 96 h with medium supplemented with carnosine at concentrations of 20, 40 and 50 mM. Following incubation, dehydrogenase activity, cellular adenosine triphosphate concentration (ATP), caspase activity, lactate dehydrogenase (LDH) release and the rate of DNA synthesis were determined. After 96 h of carnosine treatment a significant reduction in cellular ATP and dehydrogenase activity was detected already at a concentration of 20 mM carnosine. Carnosine (50 mM) reduced ATP concentration to 42.7 ± 13.5% (n = 6) and dehydrogenase activity to 41.0 ± 19.3% (n = 6) compared to untreated cells. Additional experiments revealed no sign of enhanced apoptosis or necrosis in the presence of carnosine. However, a quantitative bromo-desoxy-uridine-based proliferation assay demonstrated a clear effect of carnosine on DNA synthesis reducing its rate down to 50% (2 cultures) and 10% (4 cultures). Therefore, it can be concluded that carnosine is obviously able to inhibit proliferation of cells derived from glioblastoma. Since it is a naturally occurring substance that appears to be non-toxic to normal tissue and is able to penetrate the blood–brain barrier it may be a candidate for a therapeutic agent that may reduce proliferation of neoplastic cells even in vivo and especially in cases of glioblastoma multiforme.     

原花青素诱导胃癌SGC-7901细胞凋亡及其机制的研究

为探讨原花青素对人胃癌SGC-7901细胞增殖及凋亡的影响及其可能的作用机制,以体外培养的SGC-7901细胞为研究对象,经一定浓度的原花青素作用后,用MTT法及流式细胞仪检测细胞增殖抑制及凋亡情况,Real-time PCR技术及免疫组化法检测Bcl-2、Bax mRNA和相关蛋白表达的含量。结果表明,不同浓度的原花青素不仅能有效抑制SGC-7901细胞增殖,还可诱导细胞凋亡,且抑制增殖及促进凋亡作用呈浓度和时间依耐性;Real-time PCR及免疫组化试验中显示,随着原花青素浓度的增加,Bcl-2mRNA及相应蛋白表达逐渐减少,Bax mRNA和相关蛋白表达逐渐增加。因此,原花青素对人胃癌SGC-7901细胞具有明显的抑制作用,其作用机制可能与上调Bcl-2蛋白和下调Bax蛋白水平有关。     

大黄素抑制胃癌细胞糖酵解并促进凋亡

目的:探讨大黄素对人胃癌BGC-823细胞凋亡及糖酵解的影响。方法:采用不同浓度大黄素(30μmol/L、90μmol/L、180μmol/L)、磷脂酰肌醇3-激酶(Phosphatidylinositol 3 kinase,PI3K)抑制剂处理人胃癌BGC-823细胞,通过四甲基偶氮唑盐(MTT)检测细胞活力,采用试剂盒检测细胞葡萄糖消耗及乳酸水平,western blotting检测细胞己糖激酶Ⅱ、Bcl-2相关蛋白(Bcl-2 Associated X Protein,Bax)、PI3K、人低氧诱导因子1α(Human Hypoxia-inducible factor 1α,HIF-α)的表达。结果:大黄素能浓度依赖性的抑制BGC-823细胞增殖、葡萄糖消耗,降低乳酸水平;并降低己糖激酶Ⅱ的表达,促进凋亡蛋白Bax表达。PI3K抑制剂可抑制胃癌细胞糖酵解水平,而将大黄素与PI3K抑制剂联合使用后,与单一抑制剂组比,对细胞糖酵解抑制水平进一步加强,大黄素可下调PI3K下游蛋白及HIF-α的表达。结论:大黄素对人胃癌BGC-823细胞的增殖抑制作用其作用机制与调节PI3K途径及HIF-α,并抑制己糖激酶Ⅱ表达降低胃癌细胞糖酵解水平相关。     

miR-148a通过靶向调节己糖激酶2基因抑制乳腺癌细胞糖酵解和细胞增殖能力

为了探讨miR-148a及己糖激酶2（hexokinase 2,HK2）基因对人乳腺癌细胞糖酵解代谢途径的影响和可能机制,利用实时荧光定量PCR（real-time fluorescent quantitative PCR,qRT-PCR）检测多种乳腺癌细胞系中miR-148a的表达量,从中筛选miR-148a表达量相对较低的乳腺癌细胞系作为研究对象。再通过观察miR-148a表达量的变化对乳腺癌细胞葡萄糖摄取量、乳酸生成量和细胞增殖指标的影响,以探究miR-148a对乳腺癌细胞糖代谢能力的影响。随后,通过TargetScan在线数据库预测miR-148a和HK2基因的靶向关系,再通过双荧光素酶报告实验、Western免疫印迹以及基因回复实验进行验证,以进一步明确miR-148a和HK2在乳腺癌细胞的糖酵解代谢途径中的作用机制。通过qRT-PCR发现miR-148a在多种乳腺癌细胞系表达降低,尤其是在乳腺癌细胞系MDA-MB231中表达量显著降低（P<0.000 1）。过表达miR-148a使MDA-MB231细胞的葡萄糖摄取量、乳酸生成量、细胞增殖指标均显著下降（P<0.01）;而抑制miR-148a表达使MDA-MB231细胞葡萄糖摄取量、乳酸生成量、细胞增殖指标均显著上升（P<0.01）。通过TargetScan在线数据库预测得出,miR-148a与HK2基因3′非编码区（3′-untranslated region,3′-UTR）具有部分结合位点;而双荧光素酶报告实验发现miR-148a与野生型HK2基因的3′-UTR荧光素酶报告载体结合,不与突变型HK2基因的3′-UTR结合。Western免疫印迹检测结果表明,过表达miR-148a使MDA-MB231细胞中HK2蛋白表达量显著下降（P＜0.000 1）,而抑制miR-148a表达则促进HK2蛋白表达量显著上升（P<0.05）。基因回复实验显示,过表达HK2基因使MDA-MB231乳腺癌细胞的葡萄糖摄取量、乳酸生成量、细胞增殖指标显著上升（P＜0.01）;将过表达miR-148a载体与过表达HK2载体共转染MDA-MB231细胞,miR-148a逆转了HK2所致的葡萄糖摄取量增加和乳酸生成量上升,并抑制细胞增殖。因此,研究提示,miR-148a可通过靶向抑制HK2基因表达而抑制乳腺癌细胞MDA-MB231糖酵解代谢和细胞增殖。     

东亚钳蝎氯毒素通过下调PKM2介导的有氧糖酵解抑制神经胶质瘤细胞的增殖活性

东亚钳蝎氯离子通道毒素(Buthus martensii Karshch chlorion channel toxin,BmK CT)是一类短链神经毒素,在体内和体外均能有效抑制神经胶质瘤细胞侵袭和增殖。然而,BmK CT抑制胶质瘤细胞增殖活性的机制尚不清楚。本研究采用代谢组学的方法探索BmK CT抑制人脑神经胶质瘤细胞增殖的分子机制。首先,通过蛋白质表达纯化获得带有谷胱甘肽S转移酶(glutathione S-transferase, GST)标签的BmK CT蛋白和GST蛋白。利用圆二色谱检测两种蛋白质均具有α-螺旋二级结构,并且融合蛋白质GST-BmK CT热稳定性较好。通过噻唑蓝(methylthiazolyldiphenyl-tetrazolium bromide, MTT)法检测GST-BmK CT对神经胶质瘤细胞(U251和A172)增殖的影响。结果显示,与GST处理组相比,1μmol/L GST-BmK CT处理组对U251细胞的抑制率更明显(U251细胞19±1.1 vs. 2.25±0.95,P<0.001, 48 h; A172细胞12±1.4 vs. 2.25±1.25,P<0.001, 48 h)。利用气相色谱-质谱联用仪(gas chromatography-mass spectrometry, GC-MS)分析鉴定出细胞内的63种代谢物,通过通路分析和聚类分析证实,GST-BmK CT处理影响神经胶质瘤细胞的有氧糖酵解。根据峰面积统计数据显示,GST-BmK CT处理降低胞内丙酮酸的含量。GST-BmK CT处理组相比GST组,明显下调胞外培养基的乳酸分泌(16.33±3.78 vs. 35.6±2.31,P<0.001, 48 h),葡萄糖消耗(2.04±0.09 vs. 2.64±0.04,P<0.05, 48 h)和胞内腺苷三磷酸(ATP)含量(633.79±0.001 vs. 5392.71±266.67,P<0.05, 48 h)。结果表明,GST-BmK CT通过下调胶质瘤细胞有氧糖酵解水平降低ATP的生成。实时荧光定量PCR和蛋白质免疫印迹结果显示,GST-BmK CT降低U251细胞丙酮酸激酶(pyruvate kinase M2, PKM2)在转录水平和翻译水平的表达,进一步发现GST-BmK CT通过下调低氧诱导因子(hypoxia inducible factor-1α, HIF-1α)降低PKM2在转录水平的表达。以上结果表明,BmK CT通过下调HIF-1α的表达,降低PKM2介导的有氧糖酵解从而抑制神经胶质瘤细胞的增殖活性。     

Bcl-2/C-Raf双基因“敲低”抑制人结肠癌细胞增殖

 RNA干扰是一种具有序列特异性的基因沉默,能够触发具有相应序列的mRNA的降解.构建具有双靶点的RNAi质粒表达载体,与单靶点表达载体比较,探讨其对结肠癌细胞增殖的抑 制作用.本研究分别构建了针对Bcl-2、C-Raf 和Bcl-2/C-Raf靶基因的质粒表达载体,通过Lipofectamine TM2000介导转染人结肠癌细胞系HCT-8后,检测相应转染组靶基因的mRNA和蛋白质表达量,测定各组细胞活性,研究RNAi对各组癌细胞增殖的抑制率.结果表明,分别转染3种质粒表达载体后,3组结肠癌细胞中相应靶基因的mRNA和蛋白质表达量均降低;转染双靶点干扰质粒的试验组;其细胞活性低于单靶点组;对于针对Bcl-2, C-Raf和Bcl-2/C-Raf基因的3组干扰实验,RNAi对结肠癌细胞增殖的抑制率分别为43.87%,40.64% 和63.85%.RNAi是结肠癌细胞中的一种功能途径,以质粒作为表达载体,同时具备Bcl-2/C-Raf双靶点的表达载体,对结肠癌细胞增殖的抑制作用要明显优于单靶点表达载体,双靶点质粒表达载体在结肠癌的基因治疗中是有潜力的.